A leader in the success game: Intercept Pharmaceuticals Inc. (ICPT) Stock


B. Riley Securities raised the price target for the Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) stock from “a Neutral” to “a Buy”. The rating was released on January 11, 2022, according to finviz. We previously noted in another research note published on August 20, 2021 by Goldman that downgraded the stock from a Neutral to a Sell with a price target of $10 for ICPT stock. The research report from B. Riley Securities has downgraded the stock from Buy to Neutral, with a price target set at $18. The stock was upgraded by H.C. Wainwright, who disclosed in a research note on March 12, 2021, from Sell to Neutral and set the price objective to $21. In their research brief published February 23, 2021, H.C. Wainwright analysts downgraded the Intercept Pharmaceuticals Inc. stock from Neutral to Sell with a price target of $25.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.


The latest trade, Performances and Moving Averages give us the following Picture

The share price of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) dipped -16.85% to close Wednesday’s market session at $14.85, lower as compared to yesterday’s close. The stock price fluctuated between $14.25 and $17.62 throughout the trading session with the volume trading being 2982744 shares, which represented a significant variation when compared to the three months average volume of 915.17K shares. The firm’s stock price fluctuated -13.36% within the last five trades and -18.23% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -16.53% in the last 6 months and 16.75% was added to its value over the previous 3 months. ICPT stock is trading at a margin of -15.51%, -9.01% and -7.01% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

As of the close of trading, ICPT deals in the Healthcare domain. The stock is trading -30.12 percent below its 52-week high and 37.37 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -17.7. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Intercept Pharmaceuticals Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?

With regard to the profitability of the company, the operating margin is currently at -16.00 percent and the profit margin is -20.50 percent, and the company has reported a gross margin of 99.30 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.

The stock’s market cap achieved a total value of $609.74 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 1.93 that mirrors the cost to be found for sales by the market.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 1.20 percent of Intercept Pharmaceuticals Inc. shares are owned by insiders, and 70.10 percent are held by financial institutions.


Please enter your comment!
Please enter your name here